Aim: The goal of this study was to evaluate the incidence of myocardial infarction, cancer and death in relation to use of hormone replacement therapy (HRT). Methods : Nine years' follow up of an urban cohort of peri-/postmenopausal women was undertaken. Local and national registers were used for retrieval of events. Results: The incidence of myocardial infarction per 1,000 person-years in users and non-users was 0.61 (5/962) and 2.20 (92/4759) respectively, adjusted relative risk (RR) 0.37; 95% confi dence interval 0.15-0.90. Rates of mortality from cardiovascular disease and cancer were 0.36 and 1.10, p= 0.058, and 2.60 and 2.09, p=0.360, respectively. In terms of all-cause mortality the adjusted RR was 1.02; 0.69- 1.52, incidence of cancer 1.28; 1.01-1.64, breast cancer 1.52; 1.01-2.28 and endometrial cancer 3.61; 1.54-8.46 . Conclusions: Women affirming use of HRT had a lower incidence of myocardial infarction. Further studies are needed to assess whether the absence of effect on total mortality may be accounted for by an increased cancer risk.
Grady D., Rubin SM, Petitti DB, Fox CS, Black D., Ettinger B., et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med1992; 117: 1016-37.
2.
Grodstein F. , Stampfer MJThe epidemiology of coronary heart disease and estrogen replacement in postmenopausal women. Prog Cardiovasc Dis1995; 38: 199-210.
3.
Hulley S., Grady D., Bush T., Furberg C., Herrington D., Riggs B., et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. Heart and Estrogen/progestin Replacement Study (HERS) Research Group. JAMA1998; 280: 605-13.
4.
Colditz GA, Hankinson SE, Hunter DJ, Willett WC, Manson JE, Stampfer MJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. N Engl J Med1995 ; 332: 1589-93.
5.
Collaborative Group on Hormonal Factors in Breast Cancer.Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52705 women with breast cancer and 108411 women without breast cancer. Lancet1997; 350: 1047-59.
6.
Bergkvist L. , Adami HO, Persson I., Hoover R., Schairer C.The risk of breast cancer after estrogen-progestin replacement. N Engl J Med1989; 321: 293-7.
7.
Risch HA, Howe GRMenopausal hormone usage and breast cancer in Saskatchewan: A Recode-Linkage Cohort Study. Am J Epidemiol1994; 139: 670-83.
8.
Persson I., Adami HO, Bergkvist L., Lindgren A., Pettersson B., Hoover R., et al. Risk of endometrial cancer after treatment with oestrogen alone or in conjunction with progestogens: results of a prospective study. Br Med J1989; 298: 147-51.
9.
Sourander L. , Rajala T., Räihä I., Maäkinen J., Erkkola R., Helenius H.Cardiovascular and cancer morbidity and mortality and sudden cardiac death in postmenopausal women on oestrogen replacement therapy (ERT). Lancet1998; 352: 1965-69.
10.
Grady D., Wenger NK, Herrington D., Khan S., Furberg C., Hunninghake D., et al. Postmenopausal hormone therapy increases risk for venous thromboembolic disease. The Heart and Estrogen/progestin Replacement Study. Ann Intern Med2000; 132: 689-96.
11.
Wilson PW, Garrison RJ, Castelli WPPostmenopausal estrogen use, cigarette smoking, cardiovascular morbidity in women over 50. The Framingham Study. N Engl J Med1985; 313: 1038-43.
12.
Henderson BE , Paganini-Hill A., Ross RKDecreased mortality in users of estrogen replacement therapy. Arch Intern Med1991 ; 151: 75-8.
13.
Petitti DB, Perman JA, Sidney S.Noncontraceptive estrogens and mortality; long-term follow-up of women in the Walnut Creek Study. Obstet Gynecol1987 ; 70: 289-93.
14.
Folsom AR, Mink PJ, Sellers TA, Hong CP, Zheng W., Potter JDHormonal replacement therapy and morbidity and mortality in a prospective study of postmenopausal women. Am J Public Health1995; 85: 1128-32.
15.
Criqui MH, Suarez L., Barrett-Connor E., McPhillips J., Wingard DL, Garland C.Postmenopausal estrogen use and mortality: results from a prospective study in a defi ned, homogeneous community. Am J Epidemiol1988; 128: 606-14.
16.
Ettinger B. , Friedman GD, Bush T., Quesenberry CPReduced mortality associated with long-term postmenopausal estrogen therapy. Obstet Gynecol1996; 87: 6-12.
17.
Grodstein F. , Stampfer MJ, Colditz GA, Willett WC, Manson JE, Joffe M., et al. Postmenopausal hormone therapy and mortality. N Engl J Med1997; 336: 1769-75.
18.
Vandenbroucke JPPostmenopausal oestrogen and cardioprotection . Lancet1991; 337: 833-4.
19.
Posthuma WF , Westendorp RG, Vandenbroucke JPCardioprotective effect of hormone replacement therapy in postmenopausal women: is the evidence biased?Br Med J1994; 308: 1268-9.
20.
Sturgeon SR , Schairer C., Brinton LA, Pearson T., Hoover RNEvidence of a healthy estrogen user survivor effect. Epidemiology1995; 6: 227-31.
21.
Trell E.Community-based preventive medical department for individual risk factors assessment and intervention in an urban area. Prev Med1983; 12: 397-402.
22.
Berglund G. , Eriksson K-F., Israelsson B., Kjellström T., Lindgärde F., Mattiasson I., et al. Cardiovascular risk groups and mortality in an urban Swedish male population: the Malmö Preventive Project. J Intern Med1996; 239: 489-97.
23.
Swedish National Bureau of Statistics.Swedish socio-economic classifi cation. Stockholm : Swedish National Bureau of Statistics, Stockholm, Sweden 1995 (in Swedish).
24.
National Board on Health and Welfare.Värdering av diagnoskvaliteten för akut hjärtinfarkt i tre svenska län. Artikelnr 1997-84-8 , Stockholm, Sweden 1997 (in Swedish).
25.
Causes of death1995. Stockholm , Sweden: National Board of Health and Welfare. Centre of Epidemiology, 1997 (ISBN 91-7201-188-2).
26.
Cancer incidence in Sweden 1995. The Swedish Cancer Registry . Stockholm, Sweden: Centre of Epidemiology, National Board of Health and Welfare, 1998 (ISBN 91-7201-238-2).
27.
Tydén P., Hansen O., Janzon L.Intra-urban variations in incidence and mortality in myocardial infarction. A study from the myocardial infarction register in the city of Malmö, Sweden . Eur Heart J1998; 19: 1795-1801.
28.
Classification of causes of death in Swedish statistics. Reports on Statistical Co-ordination 1990:3. Stockholm, Sweden: Statistics Sweden, 1990 (ISBN 0082-0029).
29.
Norusis MJSPSS/PC+ Statistics 4.0 for the IBM PC/XT/AT and PS/2. Chicago: SPSS, 1990.
30.
Kaplan EL, Meier P.Nonparametric estimation from incomplete observations. J Am Stat Assoc1958; 53: 457-81.
31.
Cox DRRegression models and life tables. J R Stat Soc1972; 34: 187-220.
32.
Merlo J., Janzon L., Berglund G., Hovelius B., Hedblad B., Wirfält E., et al. Self-administered questionnaire is a simple and valid method compared to a personal diary for assessment of current exposure to hormone therapy-an analysis of 16,060 women. Am J ofEpidemiol2000; 152: 788-92.
33.
Marmot MG, McDowall MEMortality decline and widening social inequalities. Lancet1986; ii: 274-6.
34.
The Writing Group for the PEPI Trial.Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. JAMA1995; 273: 199-208.
35.
Guetta V., Cannon III ROCardiovascular effects of estrogen and lipid-lowering therapies in postmenopausal women. Circulation1996; 93: 1928-37.
36.
Design of the Women's Health Initiative clinical trial and observational study. The Women's Health Initiative Study Group.Control Clin Trials1998; 19: 61-109.
37.
Garne JP, Aspegren K., Möller T.Validity of breast cancer registration from one hospital into the Swedish National Cancer Registry 1961-1970. Acta Oncol1990; 29: 125-8.
38.
Garne JP, Aspegren K., Möller T.Validity of breast cancer registration from one hospital into the Swedish National Cancer Registry 1971-1991. Acta Oncol1995; 34: 153-6.
39.
Barrett-Connor E.Postmenopausal estrogen and prevention bias . Ann Intern Med1991; 115: 455-6.
40.
Petitti DBCoronary heart disease and oestrogen replacement therapy: can compliance bias explain the results of observational studies. Ann Epidemiol1994; 4: 115-18.
